Home › Mutual Funds › Nippon Mutual Fund › Nippon India Pharma Fund - Direct Plan - Bonus Plan
Latest NAV & returns of NIPPON INDIA PRIVATE LTD.

Nippon India Pharma Fund - Direct Plan - Bonus Plan

Add To Compare

previously known as Reliance Pharma Dir Bns until

571.803 (-0.305%)
NAV on October 31, 2025
Category Equity:
Sector - Healthcare
Total Assets 8,114 cr
Turnover Ratio 14.27%
Expense Ratio 0.91%
Exit Load 1.00%if redeemed within
1 Months0.00%if redeemed after 1 Months
Returns
  • 1M: 3.31%
  • 1Y: 0.38%
  • 3M: -3.31%
  • 3Y: 21.98%
  • 6M: 3.50%
  • 5Y: 19.29%
Min Investment 5,000
ADDITIONAL INFO
Fund Manager Sailesh Raj Bhan (Since over 20 years) Kinjal Desai (Since over 7 years)
ISIN INF204K01I27
Fund Family Nippon
P/E Ratio 35.64
P/B Ratio 5.65
Launch Date January 01, 2013
Benchmark BSE Healthcare TR INR
ASSET ALLOCATION
CREDIT QUALITY (%)
AAA -
AA -
A -
BBB -
BB -
B -
Below B -
Unrated -
RISK MEASURES (3 yrs)
vs BSE Healthcare TR INR

Alpha -0.21
Beta 0.91
R-Squared 94.82
Info Ratio -0.48
Tracking Err 3.74
Sortino 1.722
Sharpe 0.961
Std Dev 15.249
Risk -
INVESTMENT OBJECTIVE

The primary investment objective of the scheme is to seek to generate consistent returns by investing in equity and equity related or fixed income securities of Pharma and other associated companies.

View Factsheet
-
Best Sector Healthcare Funds
NAME LATEST
NAV		 RETURNS
1y     		FUND
ASSETS		 Expense
RATIO		 RISK
Icici
ICICI Prudential Pharma Healthcare and Diagnostics (P.H.D) Fund Direct Growth
43.580 5.42% 6,227 cr 1.03% -
Sbi
SBI Healthcare Opportunities Fund Direct Growth
499.097 3.60% 3,933 cr 0.91% -
Uti
UTI Healthcare Fund-Growth Option- Direct
328.870 3.03% 1,097 cr 1.3% -


Other plans of Nippon India Pharma

Data Partner
Click here to visit AMC website and
read all scheme related documents Nippon Fund